Search
Carbenoxolone
go.drugbank.com/drugs/DB02329ExperimentalAntidiuretic side effects are frequent, but otherwise the drug is low in toxicity. [PubChem]
PIKA rabies vaccine
go.drugbank.com/drugs/DB17963InvestigationalPIKA rabies vaccine is a novel vaccine developed by YS Biopharma.
2G7
go.drugbank.com/drugs/DB18589Experimental2G7 is an anti-TGF-beta monoclonal antibody developed by Genentech.
Istradefylline
go.drugbank.com/drugs/DB11757ApprovedInvestigationalIstradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy.
Rimonabant
go.drugbank.com/drugs/DB06155ApprovedWithdrawnRimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite.
Technetium Tc-99m medronate
go.drugbank.com/drugs/DB09138ApprovedInvestigationalFollowing intravenous injection, single photon emission computed tomography (SPECT) is performed to detect the gamma ray emmitted by the decay of Technetium-99m to Technetium-99.
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB10076ApprovedHaemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen is a vaccine for intramuscular injection used in the prevention of invasive disease caused by *Haemophilus
Benzoic acid
go.drugbank.com/drugs/DB03793ApprovedInvestigationalTotal Positive and Negative Syndrome Scale scores dropped by 21% compared to placebo.
Citraconic acid
go.drugbank.com/drugs/DB04734ExperimentalCitraconic acid is one of the isomeric dicarboxylic acids produced by the distillation of citric acid, or as metabolites by microorganisms, cis-CH3-C(CO2H)=CHCO2H; the trans-isomer is mesaconic acid.
Torcetrapib
go.drugbank.com/drugs/DB06281InvestigationalTorcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination